Moderators: Jill Alldredge, MD & Jessica McAlpine, MD

• Risk Stratification of Stage I Grade 3 Endometrioid Endometrial Carcinoma – Speaker: W. Zammarrelli
• Molecular Classification of Endometrial Carcinomas: A Single-Institution Review – Speaker: E. Rios-Doria
• A Molecular Perspective: Racial Disparities in Uterine Serous Carcinoma – Speaker: O. Lara
• Molecular Subtype Stratified Response to Adjuvant Therapy in Endometrial Cancer – Speaker: A. Jamieson
• MLH1 Hypermethylation Predicts Poor Outcomes with Pembrolizumab in Recurrent Endometrial Cancer – Speaker: L. Borden
• To Test or Re-Test, that is the Question: Comparison of the Mismatch Repair Deficiency between Primary and Recurrent Sites of Uterine Cancers – Speaker: R. Previs
• Cost-Effectiveness Analysis of Tumor Molecular Testing in Stage III Endometrial Cancer – Speaker: T. Orellana
• Distillation – Speaker: M. Powell
• RNAseq Correlative Biomarkers IFIT1B and VSTM5 Predict Progression Free Survival and Clinical Benefit in a Multi-Site Phase I/II Trial of Olaparib and Tremelimumab for gBRCAm Recurrent Ovarian Cancer – Speaker: S. Adams
• Turning Cold into Hot: Combination of Pembrolizumab with Bevacizumab and Oral Metronomic Cyclophosphamide Increases Immune Cell Migration into the Tumor Microenvironment in Responding Patients with Recurrent Ovarian Cancer – Speaker: N. Gaulin
• The Role of Mesenchymal Stem Cells in the Ovarian Cancer Precarcinoma Microenvironment – Speaker: T. Orellana
• Defining the Impact of Chromobox 2 on the Immune Tumor Microenvironment of High Grade Serous Ovarian Carcinoma – Speaker: L. Brubaker
• Distillation – Speaker: K. Odunsi

This session was recorded live at the 2022 AM on Women’s Cancer in March 2022.